"Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal"

Join us live on Thursday, October 1, 2020, from 3:00 PM ET to 4:00 PM ET • Hosted jointly by the TxPharm & Pediatric Communities of Practice

"Three‐year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal."
(Am J Transplant . 2020 May 14. doi: 10.1111/ajt.16005.)

In this article:
CRADLE was a 36‐month multicenter study in pediatric (1-to-18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced‐exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6‐month posttransplant or continue mycophenolate mofetil + standard‐exposure TAC (MMF + sTAC; n = 54) with corticosteroids... The overall incidence of adverse events (AEs) and serious AEs was comparable between groups. Rejection was the leading AE for study drug discontinuation in the EVR + rTAC group. In conclusion, though AE‐related study drug discontinuation was higher, an EVR + rTAC regimen represents an alternative treatment option that enables withdrawal of steroids as well as reduction of CNIs for pediatric kidney transplant recipients. (ClinicalTrials.gov: NCT01544491)

Speakers:
Robert Ettenger, MD • David Geffen School of Medicine at UCLA, Los Angeles, CA
Nicole Hayde, MD, MS • Albert Einstein College of Medicine, New York, NY

Moderator:
Justin Chen, PharmD • New York-Presbyterian Hospital, New York, NY

AST/AJT Journal Clubs are free for both members and non-members. Pre-registration is required.

Register

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.